197
Participants
Start Date
July 17, 2019
Primary Completion Date
December 12, 2023
Study Completion Date
June 30, 2026
Nivolumab and Ipilimumab
Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
chemotherapy
Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
Masaryk Memorial Cancer Institute, Brno
University Hospital Hradec Kralove, Hradec Králové
CHRU de Lille - Hopital Huriez, Lille
Hôpital Privé Jean Mermoz, Lyon
Gustave Roussy, Villejuif
Charite - Universitaetsmedizin Berlin, Berlin
Kliniken Essen-Mitte, Essen
Universitaetsklinikum Freiburg, Freiburg im Breisgau
Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center, Hamburg
SLK-Kliniken Heilbronn, Heilbronn
Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden, Leipzig
Klinikum Rechts der isar Der Technische Universitaet Muenchen - Klinikum Rechts Der Isar, München
Universitaetsklinikum Tuebingen-Uni Kliniken Berg, Tübingen
Rambam Health Care Campus, Oncology Institute, Haifa
Rabbin Medical Centre - Tel Aviv, Tel Aviv
Azienda Ospedaliera a Papa Giovanni XXIII, Bergamo
Istituto Europeo di Oncologia, Milan
"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale", Napoli
Oslo University Hospital - Ullevaal Hospital, Oslo
Institut Catalan d'Oncologia - ICO Badalona, Badalona
Hospital Universitario 12 de Octubre, Madrid
Complejo Hospitalario A, Pamplona
Hospital Clinico Universitario de Valencia, Valencia
Cambridge University Hospital NHS, Cambridge
Royal Marsden Hospital, London
University College London Hospitals NHS Foundation Trust, London
Royal Marsden Hospital, Sutton
Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK